Absolute Contraindications to Anticoagulation in Patients with High CHA₂DS₂-VASc Score

Major Absolute Contraindications

The American College of Cardiology recommends that patients with high CHA₂DS₂-VASc scores should not receive anticoagulation if they have active major bleeding, severe uncontrolled hypertension, or a history of intracranial hemorrhage with high risk of recurrence 1, 2
Active major bleeding represents an absolute contraindication to anticoagulation, as it requires medical intervention 1
Recent or planned major surgery/procedure with high bleeding risk is an absolute contraindication to anticoagulation, due to the significant risk of hemorrhagic complications 1
Severe uncontrolled hypertension, particularly when blood pressure consistently exceeds 180/120 mmHg, significantly increases bleeding risk and is an absolute contraindication to anticoagulation 2
A history of intracranial hemorrhage with high risk of recurrence or severe sequelae is an absolute contraindication to anticoagulation 1
End-stage liver disease with coagulopathy and elevated bleeding risk is an absolute contraindication to anticoagulation 1
Severe thrombocytopenia (platelet count <50,000/μL) is an absolute contraindication to anticoagulation 1
Hypersensitivity or allergy to all available anticoagulant medications is an absolute contraindication to anticoagulation 1

Recent non-major bleeding requires evaluation of bleeding source and risk of recurrence before initiating anticoagulation 1
High risk of falls, particularly in elderly patients with a history of traumatic falls, requires careful consideration before initiating anticoagulation 3
Cognitive impairment with inability to comply with medication regimen and without adequate caregiver support is a relative contraindication to anticoagulation 1
Chronic alcohol abuse with high risk of non-compliance and traumatic injury is a relative contraindication to anticoagulation 1

The European Heart Journal recommends calculating bleeding risk using validated tools such as HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history, labile INR, elderly, drugs/alcohol) 3
The European Heart Journal suggests balancing stroke risk against bleeding risk, as the higher the CHA₂DS₂-VASc score, the greater the potential benefit of anticoagulation despite bleeding risks 2, 4

The European Heart Journal notes that the fear of falls may be overstated in clinical practice, as a patient would need to fall approximately 300 times per year for the risk of intracranial hemorrhage to outweigh the benefit of anticoagulation in stroke prevention 3
Antiplatelet therapy is not recommended as an alternative to anticoagulation for stroke prevention in AF patients with high CHA₂DS₂-VASc scores, according to the European Heart Journal 2

Post-bleeding management involves considering resuming anticoagulation after bleeding is controlled, potentially with lower doses or alternative agents, as recommended by the American College of Cardiology 1
Perioperative management may require temporary interruption of anticoagulation, with bridging therapy considered for those at highest risk, according to the American College of Cardiology 1
Mechanical heart valves require warfarin as the only indicated anticoagulant, as DOACs are contraindicated 5

The Watchman left atrial appendage occlusion device is indicated for patients with non‑valvular atrial fibrillation, a CHA₂DS₂‑VASc score ≥ 2 (≥ 1 in women), and contraindications to long‑term oral anticoagulation because of high bleeding risk (HAS‑BLED ≥ 3)【6】.
The FDA‑approved indication specifically covers non‑valvular AF patients who are at risk for stroke, can tolerate short‑term anticoagulation, and seek a non‑pharmacologic alternative to lifelong oral anticoagulation【6】.
A CHA₂DS₂‑VASc score ≥ 2 (or ≥ 1 in women) defines elevated thromboembolic risk and qualifies patients for LAA closure【7】【8】.

Watchman implantation should not be performed in patients with valvular AF (moderate‑to‑severe mitral stenosis or mechanical heart valves), because these individuals require lifelong anticoagulation【7】.
Aspirin monotherapy alone is ineffective for stroke prevention in atrial fibrillation and still carries bleeding risk; it should not replace anticoagulation or LAA closure【8】.

Implantation must be carried out at centers that have a multidisciplinary team—including interventional cardiology, electrophysiology, and cardiac imaging specialists—to ensure appropriate patient evaluation and procedural planning【6】.
Immediate cardiac‑surgery backup capability must be available to manage emergency complications during the procedure【6】.
Operators are required to have specific training and credentialing in left atrial appendage closure techniques before performing Watchman implantations【6】.
The center must possess transesophageal echocardiography (TEE) capability for intra‑procedural guidance and for scheduled post‑implant follow‑up assessments【6】.